Johnson & Johnson pharma sales continue to struggle
This article was originally published in Scrip
Johnson and Johnson's pharmaceutical sales continued to suffer from generic competition in the second quarter, with only the weak US dollar causing an increase of 3.1% to $6.3 billion, up from $6.1 billion in the same period last year. Indeed, without the positive currency effect of 4.4%, the decline in drug sales would have increased from 0.6% in the first quarter to 1.3% in the second.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.